Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of ipilimumab added to carboplatin and etoposide for first-line extensive-stage small cell lung cancer
2010-021863-34Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jan 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: 1-year progression-free survival. Started Jan 2011; status: completed.
02
Drugs
ipilimumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2010-021863-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021863-34.